Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Common Equity (2020 - 2025)

Historic Common Equity for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to $60.7 million.

  • SOPHiA GENETICS's Common Equity fell 4653.46% to $60.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.7 million, marking a year-over-year decrease of 4653.46%. This contributed to the annual value of $96.5 million for FY2024, which is 3628.58% down from last year.
  • SOPHiA GENETICS's Common Equity amounted to $60.7 million in Q3 2025, which was down 4653.46% from $76.7 million recorded in Q2 2025.
  • SOPHiA GENETICS's Common Equity's 5-year high stood at $289.7 million during Q3 2021, with a 5-year trough of $60.7 million in Q3 2025.
  • Over the past 5 years, SOPHiA GENETICS's median Common Equity value was $154.9 million (recorded in 2023), while the average stood at $159.7 million.
  • Per our database at Business Quant, SOPHiA GENETICS's Common Equity soared by 22086.39% in 2022 and then tumbled by 4653.46% in 2025.
  • Quarter analysis of 5 years shows SOPHiA GENETICS's Common Equity stood at $275.4 million in 2021, then decreased by 27.33% to $200.1 million in 2022, then dropped by 24.33% to $151.4 million in 2023, then plummeted by 36.29% to $96.5 million in 2024, then tumbled by 37.11% to $60.7 million in 2025.
  • Its Common Equity was $60.7 million in Q3 2025, compared to $76.7 million in Q2 2025 and $85.6 million in Q1 2025.